Management of Lung Nodules

Introduction to Lung Nodule Management

The American College of Chest Physicians recommends that solid nodules >8mm should proceed to risk assessment, and those with intermediate probability (10-70%) warrant PET-CT for further characterization 1, 2
For nodules ≥8mm, PET scan provides essential risk stratification to guide subsequent management, with 97% sensitivity and 78% specificity 2
Each nodule must be evaluated individually, as screening studies show that 85% of additional nodules in patients with one malignant nodule are actually benign 3, 4, 5

The American College of Chest Physicians explicitly states that candidates for curative treatment should not be denied therapy unless metastasis is confirmed histopathologically 3, 4, 5
Calculate malignancy probability using the Brock model, which incorporates age, smoking history, nodule size, spiculation, and location 2
Consider patient risk factors, including age, smoking pack-years, and prior malignancy history 1, 2

For nodules ≥8mm, low risk (<10%): CT surveillance at 3-6 months 1, 2
For nodules ≥8mm, intermediate risk (10-70%): PET-CT for risk stratification 1, 2
For nodules ≥8mm, high risk (>70%): consider proceeding directly to biopsy or surgical resection 1, 2
For nodules <8mm, CT surveillance at 3, 6, and 12 months, then annually for 3 years 1, 2

Part-solid nodules >8mm have significantly higher malignancy risk and warrant repeat CT at 3 months, then proceed to PET, biopsy, or resection if persistent 5, 1, 2
PET should not be used for part-solid lesions where the solid component is <8mm 4, 5

Unless there are clear infectious features, empiric antibiotics delay definitive diagnosis without clear benefit 6
Consider a short trial of antibiotics only if the patient has fever, productive cough, or other signs of active infection, and follow-up HRCT should be at 1 month 6